2024 年 ESMO 年会展示了 TORL-1-23 在铂类耐药卵巢癌患者中的持久反应，推动了 2 期试验和 DS-9606' 2024 ESMO Congress showcased TORL-1-23's durable responses in platinum-resistant ovarian cancer patients, prompting a Phase 2 trial, and DS-9606'
TORL生物治疗学在2024年的ESMO大会上介绍了其Claudin 6目标抗体药物共合体(TORL-1-23)第一阶段的最新结果。 TORL BioTherapeutics presented updated Phase 1 results for its Claudin 6-targeted antibody-drug conjugate, TORL-1-23, at the 2024 ESMO Congress. 这项研究显示,克劳丁6阳性,抗性卵巢癌患者的反应持续,因此计划进行第二阶段试验. The study showed durable responses in patients with Claudin 6 positive, platinum-resistant ovarian cancer, prompting plans for a Phase 2 trial. 另一种针对CLDN6的药物DS-9606的单独试验报告了在先进的固体瘤中早期的疗效,没有显著的毒性,突出了其进一步研究的潜力. A separate trial of DS-9606, another CLDN6-targeted drug, reported early efficacy in advanced solid tumors and no significant toxicities, highlighting its potential for further investigation.